JP Morgan Chase
VERV

JP Morgan Chase’s Verve Therapeutics VERV Stock Holding History

JP Morgan Chase’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,141,911
Closed -$12.8M – 7740
2025
Q2 		$12.8M Buy
1,141,911
+825,732
+261% +$4.71M ﹤0.01% 2333
2025
Q1 		$1.44M Sell
316,179
-101,360
-24% -$679K ﹤0.01% 4096
2024
Q4 		$2.35M Sell
417,539
-1,230,305
-75% -$6.94M ﹤0.01% 4024
2024
Q3 		$7.98M Sell
1,647,844
-43,508
-3% -$253K ﹤0.01% 2812
2024
Q2 		$8.25M Buy
1,691,352
+198,302
+13% +$1.25M ﹤0.01% 2626
2024
Q1 		$19.8M Sell
1,493,050
-565,349
-27% -$7.5M ﹤0.01% 1892
2023
Q4 		$28.7M Sell
2,058,399
-447,497
-18% -$5.55M ﹤0.01% 1561
2023
Q3 		$33.2M Buy
2,505,896
+666,910
+36% +$10.7M ﹤0.01% 1321
2023
Q2 		$34.5M Sell
1,838,986
-69,378
-4% -$1.16M ﹤0.01% 1305
2023
Q1 		$27.5M Buy
1,908,364
+119,902
+7% +$2.35M ﹤0.01% 1434
2022
Q4 		$34.6M Sell
1,788,462
-130,028
-7% -$3.45M ﹤0.01% 1304
2022
Q3 		$65.9M Buy
1,918,490
+563,852
+42% +$18M 0.01% 913
2022
Q2 		$20.7M Buy
1,354,638
+235,804
+21% +$3.65M ﹤0.01% 1592
2022
Q1 		$25.5M Buy
1,118,834
+241,536
+28% +$6.9M ﹤0.01% 1579
2021
Q4 		$32.3M Sell
877,298
-22,567
-3% -$948K ﹤0.01% 1451
2021
Q3 		$42.3M Sell
899,865
-20,387
-2% -$1.2M 0.01% 1271
2021
Q2 		$55.4M Buy
+920,252
New +$38.2M 0.01% 1171

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

JP Morgan Chase's VERV Position: Q3 2025 in Review

JP Morgan Chase sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 1,141,911 shares — an estimated $12.8M sold.

JP Morgan Chase first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $65.9M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • JP Morgan Chase reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 1,141,911 Verve Therapeutics shares in Q3 2025, an estimated $12.8M.
  • JP Morgan Chase first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • JP Morgan Chase's Verve Therapeutics position peaked at $65.9M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.